Retatrutide: What's Actually Approved, What's Actually Known, and What It Actually Costs Right Now

Search "retatrutide" and the volume is enormous — hundreds of thousands of monthly searches, plus tens of thousands more for its side effects, its dosing, and its cost. Almost none of the pages ranking for those terms will tell you the one fact that actually governs all the others: retatrutide is not an approved drug. It cannot be prescribed, dispensed, or legally sold for human use in the United States today. That is not a technicality or a "gray area" — it is the single most load-bearing fact about this compound, and it is worth confirming directly rather than taking on faith.

The status, confirmed directly against two sources

A live query against the FDA's own Drugs@FDA database — the authoritative record of every approved new-drug and biologics application — returns zero matches for "retatrutide." That is not a broken search: the identical query mechanism returns real, populated results for an approved drug like tirzepatide, confirming the API itself works and the absence is meaningful, not a fluke.

Eli Lilly, the company developing retatrutide, says the same thing about its own molecule, in its own words, in a press release confirming positive Phase 3 results: "Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use⁴." That is about as unambiguous as a drug sponsor's language gets. Lilly's own investor materials, the same day, stated the company's plan to submit a Biologics License Application (BLA) — the FDA filing that starts a formal review — in the first quarter of 2027⁵. A planned filing is not a pending approval, and a filing is not a decision: submitting a BLA opens FDA's review clock, it does not shorten it. As of this writing, retatrutide remains squarely in the "investigational" column, with no approval, no pending FDA decision that has been announced, and no public timeline for one.

What retatrutide actually is

Retatrutide (Eli Lilly's internal code LY3437943) is a single peptide engineered to activate three separate hormone receptors at once — GIP, GLP-1, and glucagon — rather than the one or two most approved metabolic drugs target. The added glucagon-receptor activity is the mechanistic differentiator from GLP-1-only drugs like semaglutide and GLP-1/GIP dual agonists like tirzepatide: glucagon receptor agonism increases energy expenditure in addition to suppressing appetite, which is the proposed reason for retatrutide's larger weight-loss numbers in trials so far. It is being developed, and tested, for obesity, type 2 diabetes, knee osteoarthritis related to obesity, obstructive sleep apnea, and chronic kidney disease — a broader indication set than any single GLP-1-class drug currently carries.

What the published, peer-reviewed evidence actually shows

Retatrutide's Phase 2 data is real, published, and peer-reviewed — and it is also the most recent controlled data publicly available, since the larger Phase 3 program's results have so far been announced by press release rather than published in full.

In the Phase 2 obesity trial (338 adults, 48 weeks, published in the New England Journal of Medicine), the least-squares mean weight loss at 48 weeks was 24.2% in the 12 mg group and 22.8% in the combined 8 mg group, against 2.1% for placebo. By that measure, 83% of participants on the 12 mg dose lost 15% or more of their body weight, versus 2% on placebo. Gastrointestinal adverse events — nausea, diarrhea, vomiting, constipation — were the most common side effects, were dose-related, mostly mild to moderate, and were partially reduced by starting at a lower dose. The same trial recorded a dose-dependent increase in heart rate that peaked around 24 weeks and declined afterward¹.

In the Phase 2 type 2 diabetes trial (281 adults, published in The Lancet), HbA1c fell by up to 2.02 percentage points at 24 weeks on the 12 mg dose, against essentially no change on placebo (-0.01%) and a smaller drop on a dulaglutide comparator arm (-1.41%). Weight loss at 36 weeks reached 16.94% on the top dose. Mild-to-moderate GI adverse events occurred in 35% of the combined retatrutide group versus 13% on placebo; there were no reports of severe hypoglycemia and no deaths in the trial².

Those numbers are genuinely strong, and they are also 2023-published Phase 2 data — smaller trials, run to pick doses for the larger program, not to prove long-term safety at scale. A peer-reviewed paper describing the design of the Phase 3 program itself — covering obesity, obstructive sleep apnea, and knee osteoarthritis — was published in Diabetes, Obesity and Metabolism in January 2026³, and Lilly's own topline announcements report that several of those Phase 3 trials (branded TRIUMPH-1 through TRIUMPH-4) have since read out positively, with the pivotal TRIUMPH-1 obesity trial (2,339 participants, 80 weeks) reporting weight loss up to 28.3% at 80 weeks and 30.3% through a 104-week extension on the top dose⁴⁵. ClinicalTrials.gov's own record for that trial confirms it as a Phase 3 study, now completed, with a primary completion date of April 2026⁶. What's missing, as of this article's publication, is the full peer-reviewed manuscript for those Phase 3 results — press-release topline numbers and a published, peer-reviewed paper are not the same evidentiary standard, and the gap between them is exactly where a supplement blog tends to round "positive Phase 3 results" up to "basically approved."

What "retatrutide cost" is actually searching for

Here is the part almost nobody selling retatrutide content wants to say plainly: if there is no FDA-approved retatrutide product, there is no legitimate U.S. pharmacy price to report, no insurance formulary tier, and no legal prescription channel — commercial "cost" isn't a real category yet. So what is the quarter of a million monthly searches for "retatrutide" actually finding?

A live check of DailyMed — the National Library of Medicine's public archive of structured drug labels — turned up ten separate SPL (structured product label) filings for retatrutide-branded injectable products: pens, lyophilized-powder kits, and a microneedle patch, filed under brand names including "Salkalli" and "Esokalli," all attributed to a single filer, Guangzhou Yixin Cross-Border E-Commerce Co., Ltd⁷. These aren't hypothetical — they're written like real drug labels, with weekly titration schedules, injection-site instructions, and warnings about pancreatitis, gallbladder disease, and hypoglycemia lifted almost verbatim from approved GLP-1-class labeling. Every one of those ten filings carries an empty "openfda" field — DailyMed's own marker for "no linked FDA-approved application." A structured product label on file with DailyMed is not the same thing as FDA approval or FDA review of what's actually in the vial; DailyMed is a public archive that a labeler submits to, and its existence there confirms only that a filing was made, not that the agency verified the product's identity, purity, or safety.

This is not a hypothetical risk. An actual FDA warning letter — issued by the agency's Center for Drug Evaluation and Research on March 31, 2026, and readable directly on fda.gov — names "Retatrutide" specifically among products a seller (Gram Peptides) was marketing despite labeling them "Research Use Only" and "not intended for human consumption." FDA's own language in that letter states plainly that "evidence obtained from your website establishes that your products are intended to be drugs for human use," and that selling them violates the federal ban on introducing an unapproved new drug into interstate commerce⁸. That letter is one example FDA chose to make public; it is not evidence that every seller behaves the same way, but it is direct, current, agency-level confirmation that the "research chemical" label is, in FDA's own assessment, sometimes a fig leaf rather than an accurate description of who's actually buying and how it's actually being used.

Why this is a different situation than compounded tirzepatide

It's worth being precise about why retatrutide's situation is not simply a more extreme version of the compounded-tirzepatide question. Our explainer on tirzepatide's own shortage-and-compounding history covers narrow, real exceptions that let some compounding pharmacies legally prepare tirzepatide today — but those exceptions exist specifically because tirzepatide is an FDA-approved drug, and compounding law's core purpose is letting a pharmacy make an individualized version of something the agency has already approved. Retatrutide has no FDA-approved reference product for a compounding exception to attach to in the first place. A vial from an unregulated seller marketed as "retatrutide" is not a compounded version of an approved medicine in a narrower legal category — it's an entirely unapproved product, made by a manufacturer FDA has not inspected, verified, or reviewed, sold to a buyer who has no reliable way to confirm what's actually inside.

The bottom line, as of today

Retatrutide has real, peer-reviewed Phase 2 efficacy data, a large and apparently successful Phase 3 program, and a company that has said, in writing, when it plans to file for approval. None of that adds up to an approved drug, a legal purchase pathway, or a real commercial price today. If you're comparing it against options that are actually available now, see the tirzepatide providers we've ranked — tirzepatide is the closest FDA-approved analog in the same drug class, with a real, if narrowed, legal pathway behind it, which retatrutide currently does not have.

None of this is dosing guidance, and it can't become any until an actual approval exists — but for a reader who already has numbers in hand and just wants the arithmetic worked out, our retatrutide reconstitution calculator converts a vial size, diluent volume, and dose into a concentration and syringe reading. It is pure math on whatever you type in, not a check on the product itself: with no FDA-approved reference product behind retatrutide, there is nothing for that arithmetic to be validated against.

If and when Lilly files its BLA and FDA reaches a decision, this page will be the first thing we update — not the vendor selling it in the meantime.